Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.

• Registration after informed consent.
• Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood
• Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood
• Regular monitoring disease status and update of survival status
• Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Inclusion criteria

• Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
• 20 years
• Patients requiring systemic chemotherapy with curative intent
• Written informed consent

Exclusion criteria

• Myeloid malignancy
• Multiple myeloma
• Patients do not require systemic chemotherapy with curative intent